Emerging Causes of Drug-Induced Anaphylaxis: A Review of Anaphylaxis-Associated Reports in the FDA Adverse Event Reporting System (FAERS)

被引:104
|
作者
Yu, Roger J. [1 ]
Krantz, Matthew S. [2 ]
Phillips, Elizabeth J. [1 ]
Stone, Cosby A., Jr. [2 ]
机构
[1] Vanderbilt Univ, Med Ctr, Dept Med, Div Infect Dis, Nashville, TN USA
[2] Vanderbilt Univ, Med Ctr, Dept Med, Div Allergy Pulm & Crit Care Med, Nashville, TN USA
基金
美国国家卫生研究院;
关键词
FDA; FAERS; Anaphylaxis; Drug allergy; Death; Fatal;
D O I
10.1016/j.jaip.2020.09.021
中图分类号
R392 [医学免疫学];
学科分类号
100102 ;
摘要
BACKGROUND: Drug-induced anaphylaxis is a well-known adverse drug reaction for some drug classes, but emerging drug causes of anaphylaxis and novel mechanisms may contribute in unrecognized ways. OBJECTIVE: We sought to determine the top drugs reported in association with anaphylaxis and anaphylaxis followed by death in the Food and Drug Administration Adverse Event Reporting System (FAERS). METHODS: We reviewed the publicly available FAERS database from 1999 to 2019. Using search terms "anaphylactic shock" or "anaphylactic reaction" and sorting cases by generic drug names, we counted and trended reports to FAERS in which a drug was associated with anaphylaxis or anaphylaxis followed by death. RESULTS: From 1999 to 2019, there were 17,506,002 adverse drug events reported in FAERS, of which 47,496 (0.27%) were reported as anaphylaxis. Excluding patients without age, sex, or country data, respectively, the median age of patients in reports of anaphylaxis was 52 (interquartile range: 28), 62.71% were female, and 13,899 of 34,381 (40.43%) reports were from the United States. There were 2984 of 47,496 (6.28%) reports of anaphylaxis followed by death. Top drug classes associated with anaphylaxis in FAERS were antibiotics, monoclonal antibodies (mAbs), nonsteroidal anti-inflammatory drugs, and acetaminophen. Top drug classes associated with anaphylaxis deaths were antibiotics, radiocontrast agents, and intraoperative agents. Linear regression demonstrated reports of anaphylaxis to mAbs increasing at an average rate of 0.77% of total anaphylaxis reports per year (95% confidence interval: 0.65, 0.88) from 2.00% in 1999 to 17.37% in 2019, faster than any other drug class. CONCLUSION: Antibiotics were highly reported for anaphylaxis overall and anaphylaxis followed by death. Increasing reports were noted for anaphylaxis to mAb therapies. (C) 2020 American Academy of Allergy, Asthma & Immunology
引用
收藏
页码:819 / +
页数:13
相关论文
共 50 条
  • [31] Evaluation of Ticagrelor Bleeding Adverse Event Reports Compared to Clopidogrel in the FDA Adverse Events Reporting System (FAERS)
    Fahmy, Ahmed I.
    Mekkawy, Mohamed A.
    Abou-Ali, Adel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2017, 26 : 186 - 186
  • [32] Reports of adverse events related with second generation antipsychotics in children in the FDA adverse event reporting system (FAERS)
    Zapata, Lorenzo Villa
    Bibbs, Janese
    Crapps, Mariah
    Lumbreras, Ainhoa Gomez
    Malone, Daniel
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2022, 31 : 579 - 580
  • [33] Unveiling the Burden of Drug-Induced Impulsivity: A Network Analysis of the FDA Adverse Event Reporting System
    Fusaroli, Michele
    Polizzi, Stefano
    Menestrina, Luca
    Giunchi, Valentina
    Pellegrini, Luca
    Raschi, Emanuel
    Weintraub, Daniel
    Recanatini, Maurizio
    Castellani, Gastone
    De Ponti, Fabrizio
    Poluzzi, Elisabetta
    DRUG SAFETY, 2024, : 1275 - 1292
  • [34] Drug-Induced Gynecomastia: Data Mining and Analysis of the FDA Adverse Event Reporting System Database
    Yang, Xiuli
    Zheng, Xiaochun
    Zhang, Miaomiao
    Huang, Jinlong
    Huang, Ping
    Wang, Jiangfeng
    CLINICAL EPIDEMIOLOGY, 2024, 16 : 617 - 630
  • [35] Risk of drug-induced angioedema: a pharmacovigilance study of FDA adverse event reporting system database
    Fan, Maoxia
    Niu, Kaibin
    Wu, Xiaoqi
    Shi, Hongshuo
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [36] DRUG-INDUCED ACUTE RENAL FAILURE USING THE FDA ADVERSE EVENT REPORTING SYSTEM DATABASE
    Alhammad, A. M.
    Al Hawaj, M. A.
    Alsalman, A. J.
    Alhashem, Y. N.
    Harpe, S. E.
    Smith, W. R.
    Brophy, D. F.
    VALUE IN HEALTH, 2011, 14 (03) : A74 - A74
  • [37] A disproportionality analysis of adverse events associated with loop diuretics in the FDA Adverse Event Reporting System (FAERS)
    Xue, Zehu
    Liu, Xi
    Liu, Qifeng
    Yang, Xiuming
    Yu, Lixia
    BMC PHARMACOLOGY & TOXICOLOGY, 2025, 26 (01):
  • [38] A disproportionality analysis of sunitinib in the FDA adverse event reporting system (FAERS)
    Zou, Wenbin
    Yang, Han
    Xi, Yu
    Zeng, Chenxi
    Chen, Wei
    Fu, Xiangning
    HELIYON, 2024, 10 (17)
  • [39] Effect of Lawyer-Submitted Reports on Safety Signals in the FDA Adverse Event Reporting System (FAERS)
    Rogers, James R.
    Sarpatwari, Ameet
    Desai, Rishi J.
    Bohn, Justin M.
    Khan, Nazleen F.
    Kesselheim, Aaron S.
    Fischer, Michael A.
    Gagne, Joshua J.
    Connolly, John G.
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2016, 25 : 403 - 403
  • [40] Analysis of adverse drug reactions of Denosumab (Prolia) in osteoporosis based on FDA adverse event reporting system (FAERS)
    Li, Ruibo
    Yuan, Xingyue
    Chen, Xi
    Ou, Yili
    Chen, Jin
    FRONTIERS IN PHARMACOLOGY, 2024, 15